Particle.news
Download on the App Store
7 ARTICLES
·
3w ago

Former FDA Biologics Chief Peter Marks Joins Eli Lilly to Lead Infectious Disease and Molecule Discovery

The move, six months after his clash with HHS Secretary Robert F. Kennedy Jr., has revived scrutiny of the regulator-to-industry pipeline.

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake
Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, testifies during a Senate Health, Education, Labor and Pensions Committee hearing on the federal coronavirus response on Capitol Hill in Washington, Thursday, March 18, 2021. (AP Photo/Susan Walsh, Pool)
Image
Eli Lilly has tapped ex-FDA CBER lead, Peter Marks, as its new head of infectious disease and senior VP of molecule discovery. Image credit: JHVEPhoto via ShutterStock.com.

Overview

  • Marks confirmed to STAT that he started at Lilly Research Laboratories on Monday and said he hopes to advance infectious disease products for public health.
  • Eli Lilly said his expertise will strengthen work across existing programs and emerging areas, citing a focus on patient-benefiting science.
  • Marks resigned as CBER director in March following a dispute with Robert F. Kennedy Jr., accusing the health secretary of promoting misinformation about vaccines.
  • During nearly a decade leading CBER, he helped conceive Operation Warp Speed and oversaw reviews of vaccines, blood products, and numerous cell and gene therapies.
  • The appointment drew fresh criticism over the revolving door between regulators and industry, while a Leerink Partners analyst said Marks could bring significant value to Lilly.